Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TSVT
3451
DELISTED
2seventy bio
TSVT
| $181K | ﹤0.01% |
+19,300
| New | +$272K |
|
3452
USCB Financial Holdings
USCB
$420M
| $181K | ﹤0.01% |
14,800
-400
| -3% | -$5.3K |
|
|
GOCO
3453
DELISTED
GoHealth
GOCO
| $180K | ﹤0.01% |
17,272
-22,952
| -57% | -$204K |
|
3454
Protara Therapeutics
TARA
$233M
| $180K | ﹤0.01% |
67,000
-12,200
| -15% | -$38.5K |
|
|
LUXE
3455
LuxExperience B.V.
LUXE
$1.04B
| $179K | ﹤0.01% |
+20,131
| New | +$208K |
|
3456
Nautilus Biotechnolgy
NAUT
$114M
| $179K | ﹤0.01% |
99,500
+10,400
| +12% | +$20.1K |
|
|
HGEN
3457
DELISTED
HUMANIGEN, INC.
HGEN
| $179K | ﹤0.01% |
1,491,771
+626,071
| +72% | +$90.3K |
|
3458
Finance of America Companies
FOA
$204M
| $178K | ﹤0.01% |
13,990
-870
| -6% | -$12.7K |
|
|
AIOS
3459
AIOS Tech
AIOS
$39.4M
| $178K | ﹤0.01% |
1,559
+136
| +10% | +$15.2K |
|
3460
Summit State Bank
SSBI
| $178K | ﹤0.01% |
+11,290
| New | +$176K |
|
|
GTH
3461
DELISTED
Genetron Holdings Limited ADS
GTH
| $178K | ﹤0.01% |
53,033
+700
| +1% | +$1.92K |
|
|
SIOX
3462
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $178K | ﹤0.01% |
409,284
+47,284
| +13% | +$15.3K |
|
|
ATNX
3463
DELISTED
Athenex, Inc. Common Stock
ATNX
| $178K | ﹤0.01% |
60,276
+17,198
| +40% | +$65.2K |
|
|
DMRA
3464
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.87B
| $177K | ﹤0.01% |
6,160
-1,012
| -14% | -$42K |
|
3465
Blue Ridge Bankshares
BRBS
$335M
| $176K | ﹤0.01% |
14,100
+3,900
| +38% | +$50.5K |
|
|
APTX
3466
DELISTED
Aptinyx Inc. Common Stock
APTX
| $176K | ﹤0.01% |
618,226
+77,200
| +14% | +$22.3K |
|
3467
Minerva Neurosciences
NERV
$209M
| $175K | ﹤0.01% |
110,300
+8,500
| +8% | +$36.7K |
|
|
CLVR
3468
DELISTED
Clever Leaves Holdings Inc. Common Shares
CLVR
| $175K | ﹤0.01% |
18,977
-83
| -0.4% | -$1.19K |
|
3469
Acumen Pharmaceuticals
ABOS
$181M
| $174K | ﹤0.01% |
+32,300
| New | +$217K |
|
|
ML
3470
DELISTED
MoneyLion Inc.
ML
| $174K | ﹤0.01% |
9,333
+1,413
| +18% | +$34.8K |
|
|
PNT
3471
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $173K | ﹤0.01% |
23,700
-16,000
| -40% | -$119K |
|
3472
Clarus
CLAR
$146M
| $171K | ﹤0.01% |
21,790
-103,000
| -83% | -$1M |
|
3473
iBio
IBIO
$67.6M
| $170K | ﹤0.01% |
19,080
+16,504
| +641% | +$558K |
|
|
SYRS
3474
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $170K | ﹤0.01% |
47,235
+3,500
| +8% | +$15.2K |
|
|
CCM
3475
Concord Medical Services
CCM
$20M
| $169K | ﹤0.01% |
10,310
-950
| -8% | -$14.8K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.